Department of Pharmacy Practice, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri Hospital & Research Centre, Adichunchanagiri University, BG Nagara, Nagamangala, Karnataka 571448, India.
Curr Drug Saf. 2020;15(2):147-155. doi: 10.2174/1574886315666200311120151.
Proton pump inhibitor (PPI) is one of the most widely prescribed medicines and commonly used in gastric related disorders and there is a huge need to analyze the irrational use of PPI in a country like India. The present study was designed to describe the rational drug use and cost comparison analysis of PPI in a rural tertiary care hospital.
A prospective observational study was performed among 253 inpatients for a period of 9 months after getting ethical approval. Those who received the PPIs for any of its indications were included in the study without any gender or age restriction. US FDA guidelines were used to analyse the appropriateness of the drug use and cost comparison analysis of the branded versus generic PPIs was also performed.
Among the 253 inpatients, the majority (62%) were male and the mean age was 46±19 years. Mean hospital stay and the number of drugs in prescription were found to be 4.0 ± 1days 4.39 ±1.16 items, respectively. Pantoprazole (76%) was the most prescribed PPI even though the majority (57%) of the patients treated outside the FDA approved indication. Drug interaction has been reported in 14% and ADR in 9% of the population. The average cost of hospital stay estimated as 207.96+149.57 INR, and potential cost saving of INR 41582 was observed with generic replacement.
The study inferred irrational drug use of PPI still prevalent, that too without considering the economic impact of it on general populations. Healthcare practitioners should be aware and cautious while prescribing the PPI to identify the actual need and to choose the most cost-effective alternative 1.
质子泵抑制剂(PPI)是使用最广泛的药物之一,常用于治疗胃部相关疾病。在印度这样的国家,分析 PPI 的不合理使用情况具有重要意义。本研究旨在描述农村三级保健医院 PPI 的合理用药情况,并进行成本比较分析。
获得伦理批准后,对 253 名住院患者进行了为期 9 个月的前瞻性观察研究。研究对象为接受 PPI 治疗任何适应证的患者,无性别或年龄限制。使用美国食品药品监督管理局(US FDA)指南分析药物使用的适宜性,并对品牌和仿制药 PPI 的成本进行比较分析。
在 253 名住院患者中,大多数(62%)为男性,平均年龄为 46±19 岁。平均住院时间和处方药物数量分别为 4.0±1 天和 4.39±1.16 种。泮托拉唑(76%)是最常开的 PPI,尽管大多数(57%)患者的治疗适应证不在 FDA 批准范围内。有 14%的患者出现药物相互作用,9%的患者出现不良反应。住院费用估计为 207.96+149.57 印度卢比,使用仿制药替代可节省 41582 印度卢比。
研究表明,PPI 的不合理用药仍然普遍存在,且未考虑其对普通人群的经济影响。医疗保健从业者在开具 PPI 时应注意并谨慎,以确定实际需求并选择最具成本效益的替代药物。